
⸺ Synova Research
Alluvi Healthcare BPC-157 + TB-500 recovery & repair blend supplied as a ready-to-use pre-filled pen. Sold for research use only.
Secure checkout via UK open banking. Free shipping on orders over £100.
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
⸺ Overview
Wolverine is a combined BPC-157 and TB-500 pre-filled pen by Alluvi Healthcare. Each pen delivers 4 doses of 10mg and arrives ready for laboratory use — no reconstitution required. Researchers use it in preclinical studies of soft-tissue repair, tendon and ligament recovery, and gastrointestinal protection.
⸺ Mechanism of Action
BPC-157 modulates growth-factor and nitric-oxide signalling involved in tissue protection and repair. TB-500 (a Thymosin Beta-4 fragment) regulates actin dynamics, cell migration and tissue reorganisation. Combined, the two peptides target complementary recovery pathways in preclinical models.
⸺ Research
Animal models with BPC-157 and TB-500 describe improved tendon, ligament and muscle repair, with reduced inflammatory markers at injury sites.
Rodent studies show protective and reparative effects of BPC-157 on gastric and intestinal lining under stress and chemical injury.
Both peptides have been individually associated with microvascular formation and tissue remodelling at injury sites.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details

Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.

Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.

Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.